Matthys Cornelis van Aardt1, Greta Dreyer, Hannelie Francina Pienaar, Frank Karlsen, Siri Hovland, Karin Louise Richter, Piet Becker. 1. *Gynaecologic Oncology Unit, Department of Obstetrics & Gynaecology, University of Pretoria, Pretoria, South Africa; †Buskerud and Vestfold University College, Borre; ‡NorChip AS, Klokkarstua, Norway; §Department of Medical Virology University of Pretoria; National Health Laboratory Service; and ∥Biostatistics Unit, South African Medical Research Council, Departments of Medical Virology, and Gynaecology, University of Pretoria, Pretoria, South Africa.
Abstract
OBJECTIVES: Cervical cancer is the most common cause of cancer-related deaths among South African women. Viral types associated with cervical cancer may differ not only between countries and regions, but possibly also between human immunodeficiency virus (HIV)-infected and noninfected women. METHODS: In a population with high HIV prevalence, human papillomavirus (HPV)-type infections detected with DNA analyses were reported in a cohort of 299 women diagnosed with invasive cervical cancer. RESULTS: One hundred fifty-four women tested HIV negative, 77 tested HIV positive, and HIV status was unknown for 68 women. The mean age for HIV-positive women was 41.3 years, and that for HIV-negative women was 55.8 years (P < 0.001). Ninety-two percent of women tested HPV-DNA positive. Human papillomavirus types 16 and/or 18 were present in 62% of HIV-negative women and 65% of HIV-positive women. The 5 most common HPV types in HIV-positive women were, in decreasing frequency, HPV 16, 18, 45, 33, and 58. In HIV-negative women, the most common HPV types were HPV 16, 18, 35, and 45, followed by HPV 33 and 52. Human papillomavirus type 45 was more likely in the HIV positive compared with the HIV negative (odds ratio, 3.07; 95% confidence interval, 1.07-8.77). The HIV-positive women had more multiple high-risk HPV-type infections than did the HIV-negative women (27% vs 8%, P = 0.001). CONCLUSIONS: A high number of women in South Africa with cervical cancer are HIV positive. Without viral cross-protection, HPV vaccines should prevent around 65% of cervical cancers in this population. Human papillomavirus type 45 infection is significantly linked to HIV and important for future vaccine developments.
OBJECTIVES: Cervical cancer is the most common cause of cancer-related deaths among South African women. Viral types associated with cervical cancer may differ not only between countries and regions, but possibly also between human immunodeficiency virus (HIV)-infected and noninfected women. METHODS: In a population with high HIV prevalence, human papillomavirus (HPV)-type infections detected with DNA analyses were reported in a cohort of 299 women diagnosed with invasive cervical cancer. RESULTS: One hundred fifty-four women tested HIV negative, 77 tested HIV positive, and HIV status was unknown for 68 women. The mean age for HIV-positive women was 41.3 years, and that for HIV-negative women was 55.8 years (P < 0.001). Ninety-two percent of women tested HPV-DNA positive. Human papillomavirus types 16 and/or 18 were present in 62% of HIV-negative women and 65% of HIV-positive women. The 5 most common HPV types in HIV-positive women were, in decreasing frequency, HPV 16, 18, 45, 33, and 58. In HIV-negative women, the most common HPV types were HPV 16, 18, 35, and 45, followed by HPV 33 and 52. Human papillomavirus type 45 was more likely in the HIV positive compared with the HIV negative (odds ratio, 3.07; 95% confidence interval, 1.07-8.77). The HIV-positive women had more multiple high-risk HPV-type infections than did the HIV-negative women (27% vs 8%, P = 0.001). CONCLUSIONS: A high number of women in South Africa with cervical cancer are HIV positive. Without viral cross-protection, HPV vaccines should prevent around 65% of cervical cancers in this population. Human papillomavirus type 45 infection is significantly linked to HIV and important for future vaccine developments.
Authors: Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt Journal: AIDS Date: 2018-07-01 Impact factor: 4.177
Authors: Sally N Adebamowo; Oluwatoyosi Olawande; Ayotunde Famooto; Eileen O Dareng; Richard Offiong; Clement A Adebamowo Journal: Front Public Health Date: 2017-07-21
Authors: Ahmadaye Ibrahim Khalil; Tharcisse Mpunga; Feixue Wei; Iacopo Baussano; Catherine de Martel; Freddie Bray; Dominik Stelzle; Scott Dryden-Peterson; Antoine Jaquet; Marie-Josèphe Horner; Olutosin A Awolude; Mario Jesus Trejo; Washington Mudini; Amr S Soliman; Mazvita Sengayi-Muchengeti; Anna E Coghill; Matthys C van Aardt; Hugo De Vuyst; Stephen E Hawes; Nathalie Broutet; Shona Dalal; Gary M Clifford Journal: Int J Cancer Date: 2021-10-19 Impact factor: 7.316
Authors: Zizipho Z A Mbulawa; Keletso Phohlo; Mirta Garcia-Jardon; Anna-Lise Williamson; Charles B Businge Journal: PLoS One Date: 2022-03-09 Impact factor: 3.240
Authors: Rixongile R Rikhotso; Emma M Mitchell; Daniel T Wilson; Aubrey Doede; Nontokozo D Matume; Pascal O Bessong Journal: S Afr J Infect Dis Date: 2022-06-08
Authors: Cameron Klein; Crispin Kahesa; Julius Mwaiselage; John T West; Charles Wood; Peter C Angeletti Journal: Front Cell Infect Microbiol Date: 2020-02-12 Impact factor: 5.293